药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201971016142313.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文0.9%氯化钠注射液处方资料(仅供参考)
【英文名称】SODIUM CHLORIDE INJECTION 0.9%
【适用证】
氯化钠注射液,USP被认为是水和电解质的来源。
0.9%氯化钠注射液,USP也适用于血液透析程序中的引发液。
【用法用量】
重要管理说明:
- 氯化钠注射液,USP用于使用无菌设备进行静脉内给药。
- 请勿将柔性塑料容器串联连接,以避免因主容器中可能残留的空气而导致空气栓塞。
- 在通气静脉内给药装置上将通气孔设置到关闭位置,以防止空气栓塞。
- 使用没有任何连接的专用线路以避免空气栓塞。
- 不要对柔性塑料容器中的静脉注射溶液加压以增加流速,以避免由于容器中残余空气的不完全排空而引起的空气栓塞。
- 输液前,目测检查溶液中是否有颗粒物质和变色。解决方案应该清楚,不应有沉淀物。除非溶液清除,否则不要进行管理,容器未损坏。
- 不要通过与全血或细胞血液成分相同的给药方式混合或给予0.45%氯化钠注射液,USP。
给药信息
产品,剂量,体积,速率和给药持续时间的选择取决于患者的年龄,体重和临床状况以及伴随治疗,并且给药应由经历静脉输液治疗的医生确定。
【禁忌】
无。
【INDICATIONS AND USAGE】
Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.
0.9% Sodium Chloride Injection, USP is also indicated for use as a priming solution in hemodialysis procedures.
【DOSAGE AND ADMINISTRATION】
Important Administration Instructions:
--Sodium Chloride Injection, USP is intended for intravenous administration using sterile equipment.
--Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.
--Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.
--Use a dedicated line without any connections to avoid air embolism.
--Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container.
--Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged.
--Do not mix or administer 0.45% Sodium Chloride Injection, USP through the same administration set with whole blood or cellular blood components.
Dosing Information
The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.
【CONTRAINDICATIONS】
None.
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201971016142313.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |